The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma

Clinical Oncology

Volumn 25, Issue 11, 2013, Pages 630-638

  Oguejiofor, K K ^a   Hall, J S ^a   Mani, N ^a   Douglas, C ^a   Slevin, N J ^b   Homer, J ^c   Hall, G ^c   West, C M L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chemoradiotherapy; Head and neck cancer; Human papillomavirus (HPV); Oropharyngeal cancer; P16; Prognosis

Indexed keywords

FORMALDEHYDE; PROTEIN P16; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CONTROL; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCOREGIONAL CONTROL; MAJOR CLINICAL STUDY; MALE; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TOBACCO; TONGUE; TONSIL;

CHEMORADIOTHERAPY; HEAD AND NECK CANCER; HUMAN PAPILLOMAVIRUS (HPV); OROPHARYNGEAL CANCER; P16; PROGNOSIS;

CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884812581     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.07.003     Document Type: Article

References (41)

1. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. JPathol 1999, 189(1):12-19.
2. Gillison M.L., Koch W.M., Capone R.B., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. JNatl Cancer Inst 2000, 92(9):709-720.
3. Shiboski C.H., Schmidt B.L., Jordan R.C. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 2005, 103(9):1843-1849.
4. Ramqvist T., Dalianis T. An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. Anticancer Res 2011, 31(5):1515-1519.
5. Ramqvist T., Dalianis T. Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis 2010, 16(11):1671-1677.
6. Reddy S., Rangaiah J., Addiman S., Wareham D., Wilson P., Sefton A. Epidemiology, antibiotic resistance trends and the cost of enteric fever in East London, 2005-2010. Travel Med Infect Dis 2011, 9(4):206-212.
7. Reddy V.M., Cundall-Curry D., Bridger M.W. Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985-2006. Ann R Coll Surg Engl 2010, 92(8):655-659.
8. Gillison M.L., D'Souza G., Westra W., et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. JNatl Cancer Inst 2008, 100(6):407-420.
9. Weinberger P.M., Yu Z., Haffty B.G., et al. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 2004, 10(17):5684-5691.
10. Ragin C.C., Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007, 121(8):1813-1820.
11. Pai S.I., Westra W.H. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol 2009, 4:49-70.
12. Robinson M., Sloan P., Shaw R. Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncol 2010, 46(7):492-496.
13. van der Riet P., Nawroz H., Hruban R.H., et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 1994, 54(5):1156-1158.
14. Reed A.L., Califano J., Cairns P., et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996, 56(16):3630-3633.
15. Cairns P., Mao L., Merlo A., et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994, 265(5170):415-417.
16. Ang K.K., Sturgis E.M. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 2012, 22(2):128-142.
17. Lewis J.S., Thorstad W.L., Chernock R.D., et al. p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 2010, 34(8):1088-1096.
18. Perrone F., Gloghini A., Cortelazzi B., Bossi P., Licitra L., Pilotti S. Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making. Am J Surg Pathol 2011, 35(5):774-777. author reply 777-778.
19. Singhi A.D., Westra W.H. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010, 116(9):2166-2173.
20. Chaturvedi A.K., Engels E.A., Pfeiffer R.M., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. JClin Oncol 2011, 29(32):4294-4301.
21. Lassen P., Eriksen J.G., Hamilton-Dutoit S., Tramm T., Alsner J., Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. JClin Oncol 2009, 27(12):1992-1998.
22. Dayyani F., Etzel C.J., Liu M., Ho C.H., Lippman S.M., Tsao A.S. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010, 2:15.
23. Heath S., Willis V., Allan K., et al. Clinically significant human papilloma virus in squamous cell carcinoma of the head and neck in UK practice. Clin Oncol (R Coll Radiol) 2012, 24(1):e18-e23.
24. Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. NEngl J Med 2010, 363(1):24-35.
25. Fischer C.A., Kampmann M., Zlobec, et al. p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters. Ann Oncol 2010, 21(10):1961-1966.
26. Lassen P., Eriksen J.G., Krogdahl A., et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol 2011, 100(1):49-55.
27. Fakhry C., Westra W.H., Li S., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. JNatl Cancer Inst 2008, 100(4):261-269.
28. Posner M.R., Lorch J.H., Goloubeva O., et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011, 22(5):1071-1077.
29. Rischin D., Young R.J., Fisher R., et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. JClin Oncol 2010, 28(27):4142-4148.
30. Ukpo O.C., Flanagan J.J., Ma X.J., Luo Y., Thorstad W.L., Lewis J.S. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol 2011, 35(9):1343-1350.
31. Granata R., Miceli R., Orlandi E., et al. Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Ann Oncol 2012, 23(7):1832-1837.
32. Reimers N., Kasper H.U., Weissenborn S.J., et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007, 120(8):1731-1738.
33. Mehanna H., West C.M., Nutting C., Paleri V. Head and neck cancer-Part 2: Treatment and prognostic factors. Br Med J 2010, 341:c4690.
34. Zhang B., Tang P.Z. [Introduction to NCCN clinical practice guidelines in head and neck cancer (2009 Chinese version)]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2009, 44(9):707-709.
35. Roland N.J. Head and neck cancer: multidisciplinary management guidelines 2011, BAHNO, London. 4th ed.
36. Hafkamp H.C., Speel E.J., Haesevoets A., et al. Asubset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 2003, 107(3):394-400.
37. Weinberger P.M., Yu Z., Haffty B.G., et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. JClin Oncol 2006, 24(5):736-747.
38. Kong C.S., Narasimhan B., Cao H., et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009, 74(2):553-561.
39. Licitra L., Perrone F., Bossi P., et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. JClin Oncol 2006, 24(36):5630-5636.
40. Olthof N.C., Straetmans J.M., Snoeck R., et al. Next-generation treatment strategies for human papillomavirus-related head and neck squamous cell carcinoma: where do we go?. Rev Med Virol 2012, 22(2):88-105.
41. Stransky N., Egloff A.M., Tward A.D., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333(6046):1157-1160.